Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Time course proteomic profiling of human myocardial infarction plasma samples: An approach to new biomarker discovery

Texto completo
Autor(es):
Mostrar menos -
Silbiger, Vivian Nogueira [1, 2] ; Luchessi, Andre Ducati [1] ; Crespo Hirata, Rosario Dominguez [1] ; Lima Neto, Lidio Goncalves [1] ; Pastorelli, Carla Prisinzano [1] ; Ueda, Eric K. M. [1] ; dos Santos, Elizabete Silva [3] ; Pereira, Marcos Paulo [3] ; Ramos, Rui [3] ; Sampaio, Marcelo Ferraz [3] ; Armaganijan, Dikran [3] ; Paik, Sun H. [4] ; Murata, Yoko [4] ; Ooi, Guck T. [4] ; Ferguson, Earl W. [4] ; Hirata, Mario Hiroyuki [3, 1]
Número total de Autores: 16
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508 Sao Paulo - Brazil
[2] Univ Fed Rio Grande do Norte, Pharm Course, Dept Clin & Toxicol Anal, BR-59012570 Natal, RN - Brazil
[3] Inst Dante Pazzanese Cardiol, Sao Paulo - Brazil
[4] Sun BioMed Technol, Ridgecrest, CA - USA
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: Clinica Chimica Acta; v. 412, n. 11-12, p. 1086-1093, MAY 12 2011.
Citações Web of Science: 14
Resumo

Background: The aim of this study was to identify novel candidate biomarker proteins differentially expressed in the plasma of patients with early stage acute myocardial infarction (AMI) using SELDI-TOF-MS as a high throughput screening technology. Methods: Ten individuals with recent acute ischemic-type chest pain (< 12 h duration) and ST-segment elevation AMI (1STEMI) and after a second AMI (2STEMI) were selected. Blood samples were drawn at six times after STEMI diagnosis. The first stage (T(0)) was in Emergency Unit before receiving any medication, the second was just after primary angioplasty (T(2)), and the next four stages occurred at 12 h intervals after T(0). Individuals (n = 7) with similar risk factors for cardiovascular disease and normal ergometric test were selected as a control group (CG). Plasma proteomic profiling analysis was performed using the top-down (i.e. intact proteins) SELDI-TOF-MS, after processing in a Multiple Affinity Removal Spin Cartridge System (Agilent). Results: Compared with the CG, the 1STEMI group exhibited 510 differentially expressed protein peaks in the first 48 h after the AMI (p < 0.05). The 2STEMI group, had similar to 85% fewer differently expressed protein peaks than those without previous history of AMI (76, p < 0.05). Among the 16 differentially-regulated protein peaks common to both STEMI cohorts (compared with the CG at T(0)), 6 peaks were persistently down-regulated at more than one time-stage, and also were inversed correlated with serum protein markers (cTnI, CK and CKMB) during 48 h-period after IAM. Conclusions: Proteomic analysis by SELDI-TOF-MS technology combined with bioinformatics tools demonstrated differential expression during a 48 h time course suggests a potential role of some of these proteins as biomarkers for the very early stages of AMI, as well as for monitoring early cardiac ischemic recovery. (C) 2011 Elsevier B.V. All rights reserved. (AU)

Processo FAPESP: 06/03487-4 - Transcriptoma e proteoma em sangue periférico para pesquisa de novos marcadores de doenças cardiovasculares: estudo em infarto agudo do miocárdio
Beneficiário:Mario Hiroyuki Hirata
Linha de fomento: Auxílio à Pesquisa - Regular